Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
- NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal third quarter ended December 31, 2023.
- “We have laid a strong and exciting foundation for Immunovant,” said Pete Salzmann, M.D., chief executive officer at Immunovant.
- Financial Highlights for Fiscal Third Quarter Ended December 31, 2023:
Cash Position: As of December 31, 2023, Immunovant’s cash and cash equivalents totaled approximately $691 million. - IPR&D Expenses: There were no acquired in-process research and development expenses for the three months ended December 31, 2023.